Alnylam Pharma Loss Narrower Than Street

(RTTNews) - Alnylam Pharmaceuticals Inc (ALNY) Wednesday reported third-quarter net loss of $44 million or $0.58 per share compared with a loss of $29.7 million or $0.48 per share last year.

Revenues from collaborators for the quarter were $11 million compared with $9 million in the prior year.

Analysts polled by Thomson Reuters estimated a loss of $0.63 per share on revenues of $8.9 million for the quarter. Analysts' estimates typically exclude special items.

For the full year 2014, the now company expects its cash, cash equivalents and marketable securities balance to be greater than $860 million compared with prior guidance of $825 million.